Emergent Biosolutions, Inc. (NYSE:EBS) Chairman Fuad El-Hibri sold 3,100 shares of the stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $37.50, for a total value of $116,250.00. Following the sale, the chairman now owns 1,621,655 shares in the company, valued at approximately $60,812,062.50. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Fuad El-Hibri also recently made the following trade(s):

  • On Thursday, September 7th, Fuad El-Hibri sold 16,439 shares of Emergent Biosolutions stock. The shares were sold at an average price of $37.50, for a total value of $616,462.50.
  • On Thursday, August 31st, Fuad El-Hibri sold 5,461 shares of Emergent Biosolutions stock. The shares were sold at an average price of $37.50, for a total value of $204,787.50.
  • On Thursday, July 27th, Fuad El-Hibri sold 25,000 shares of Emergent Biosolutions stock. The shares were sold at an average price of $36.50, for a total value of $912,500.00.
  • On Thursday, July 20th, Fuad El-Hibri sold 25,000 shares of Emergent Biosolutions stock. The shares were sold at an average price of $35.50, for a total value of $887,500.00.

Shares of Emergent Biosolutions, Inc. (NYSE EBS) opened at 37.64 on Friday. The firm has a market cap of $1.55 billion, a PE ratio of 23.97 and a beta of 1.23. The stock’s 50 day moving average price is $35.89 and its 200 day moving average price is $32.31. Emergent Biosolutions, Inc. has a 12-month low of $24.47 and a 12-month high of $37.98.

Emergent Biosolutions (NYSE:EBS) last posted its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported $0.13 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.26 by $0.13. The company had revenue of $100.77 million during the quarter, compared to the consensus estimate of $111.57 million. Emergent Biosolutions had a net margin of 13.42% and a return on equity of 14.50%. Emergent Biosolutions’s quarterly revenue was up 10.4% on a year-over-year basis. During the same period in the prior year, the company posted ($0.05) EPS. On average, equities research analysts predict that Emergent Biosolutions, Inc. will post $1.54 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Emergent Biosolutions, Inc. (EBS) Chairman Sells $116,250.00 in Stock” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another website, it was stolen and republished in violation of US & international copyright and trademark laws. The original version of this article can be read at https://www.thecerbatgem.com/2017/09/09/emergent-biosolutions-inc-ebs-chairman-sells-116250-00-in-stock.html.

Several hedge funds and other institutional investors have recently bought and sold shares of EBS. Creative Planning grew its position in Emergent Biosolutions by 1.2% during the 2nd quarter. Creative Planning now owns 4,555 shares of the biopharmaceutical company’s stock worth $154,000 after purchasing an additional 55 shares in the last quarter. State of Alaska Department of Revenue grew its position in Emergent Biosolutions by 2.7% during the 1st quarter. State of Alaska Department of Revenue now owns 3,820 shares of the biopharmaceutical company’s stock worth $110,000 after purchasing an additional 100 shares in the last quarter. Louisiana State Employees Retirement System grew its position in Emergent Biosolutions by 0.7% during the 2nd quarter. Louisiana State Employees Retirement System now owns 14,200 shares of the biopharmaceutical company’s stock worth $482,000 after purchasing an additional 100 shares in the last quarter. Arizona State Retirement System grew its position in Emergent Biosolutions by 0.6% during the 2nd quarter. Arizona State Retirement System now owns 18,160 shares of the biopharmaceutical company’s stock worth $616,000 after purchasing an additional 100 shares in the last quarter. Finally, Municipal Employees Retirement System of Michigan grew its position in Emergent Biosolutions by 1.7% during the 1st quarter. Municipal Employees Retirement System of Michigan now owns 10,720 shares of the biopharmaceutical company’s stock worth $312,000 after purchasing an additional 180 shares in the last quarter. 85.44% of the stock is currently owned by institutional investors.

A number of equities research analysts have commented on the company. BidaskClub upgraded Emergent Biosolutions from a “hold” rating to a “buy” rating in a report on Friday, August 25th. Zacks Investment Research cut Emergent Biosolutions from a “buy” rating to a “hold” rating in a report on Friday, August 11th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company. Emergent Biosolutions has a consensus rating of “Buy” and a consensus target price of $44.00.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

Insider Buying and Selling by Quarter for Emergent Biosolutions (NYSE:EBS)

Receive News & Stock Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related stocks with our FREE daily email newsletter.